Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung transplant patients may get better flu protection with High-Dose vaccine

NCT ID NCT05215327

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 32 times

Summary

This study compares a high-dose flu vaccine to the standard dose in 270 lung transplant recipients who are 1 to 35 months post-transplant. The goal is to see if the high-dose vaccine triggers a stronger immune response and provides better protection against the flu. Participants will receive two doses of either vaccine within the same flu season.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.